Get started
EVOGENEEVOGENEEVOGENE

EVOGENE

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

EVGN chart


Full chart

EVGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪28.41 M‬ ILS
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−16.6 ILS
Net income (FY)
‪−86.70 M‬ ILS
Revenue (FY)
‪20.48 M‬ ILS
Shares float
‪5.28 M‬
Beta (1Y)
0.12

Employees


Employees (FY)
142
Change (1Y)
+5 +3.65%
Revenue / Employee (1Y)
‪144.22 K‬ ILS
Net income / Employee (1Y)
‪−610.59 K‬ ILS

About Evogene Ltd.


Sector
Health Technology
Industry
Biotechnology
CEO
Ofer Haviv
Website
evogene.com
Headquarters
Rehovot
Founded
1999
ISIN
IL0011050551
FIGI
BBG000PPN4T1
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EVGN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of EVGN is 534.4 ILA — it has increased by 4.51% in the past 24 hours. Watch EVOGENE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange EVOGENE stocks are traded under the ticker EVGN.
EVGN stock has risen by 18.80% compared to the previous week, the month change is a −10.54% fall, over the last year EVOGENE has showed a −82.62% decrease.
We've gathered analysts' opinions on EVOGENE future price: according to them, EVGN price has a max estimate of 4,172.23 ILA and a min estimate of 1,854.32 ILA. Watch EVGN chart and read a more detailed EVOGENE stock forecast: see what analysts think of EVOGENE and suggest that you do with its stocks.
EVGN reached its all-time high on Jan 1, 2014 with the price of 69,950.0 ILA, and its all-time low was 450.1 ILA and was reached on Dec 18, 2024. View more price dynamics on EVGN chart.
See other stocks reaching their highest and lowest prices.
EVGN stock is 6.40% volatile and has beta coefficient of 0.12. Track EVOGENE stock price on the chart and check out the list of the most volatile stocks — is EVOGENE there?
Today EVOGENE has the market capitalization of ‪28.41 M‬, it has increased by 8.32% over the last week.
Yes, you can track EVOGENE financials in yearly and quarterly reports right on TradingView.
EVOGENE is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
EVGN earnings for the last quarter are −4.89 ILA per share, whereas the estimation was −3.77 ILA resulting in a −29.70% surprise. The estimated earnings for the next quarter are −2.65 ILA per share. See more details about EVOGENE earnings.
EVOGENE revenue for the last quarter amounts to ‪6.70 M‬ ILA, despite the estimated figure of ‪10.64 M‬ ILA. In the next quarter, revenue is expected to reach ‪13.24 M‬ ILA.
EVGN net income for the last quarter is ‪−28.47 M‬ ILS, while the quarter before that showed ‪−20.48 M‬ ILS of net income which accounts for −39.03% change. Track more EVOGENE financial stats to get the full picture.
No, EVGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 142.00 employees. See our rating of the largest employees — is EVOGENE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EVOGENE EBITDA is ‪−82.74 M‬ ILS, and current EBITDA margin is −421.61%. See more stats in EVOGENE financial statements.
Like other stocks, EVGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EVOGENE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EVOGENE technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EVOGENE stock shows the sell signal. See more of EVOGENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.